GRO Biosciences secures Series B funding for gout treatment
The latest financing brings the total capital raised by GRObio to $90m.
Services
US CDC recommends routine RSV vaccination for older adults
Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer
South Korea and Australia on the rise as clinical research hubs
UK clinical trial sector must address prolonged timelines, say experts
AstraZeneca Tagrisso sNDA gains FDA priority review for lung cancer
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Otsuka cuts development for AVP-786 following Phase III flop
